HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon

International Journal of Cancer

Volumn 122, Issue 10, 2008, Pages 2233-2241

  Italiano, Antoine ^a,b   Bianchini, Laurence ^a   Keslair, Frédérique ^a   Bonnafous, Stéphanie ^c   Cardot Leccia, Nathalie ^a   Coindre, Jean Michel ^d   Dumollard, Jean Marc ^e   Hofman, Paul ^a   Leroux, Agnès ^f   Mainguené, Claire ^g   Peyrottes, Isabelle ^b   Ranchere Vince, Dominique ^h   Terrier, Philippe ⁱ   Tran, Albert ^a,c   Gual, Philippe ^a,c   Pedeutour, Florence ^a,j  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c INSERM   (France)

^d INSTITUT BERGONIÉ   (France)

^e UNIVERSITÉ JEAN MONNET   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g CENTRE HOSPITALIER PRINCESSE GRACE   (Monaco)

^h CENTRE LÉON BÉRARD   (France)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j UNIVERSITÉ CÔTE D'AZUR   (France)

more..

Author keywords

12q13 15 amplicon; DDIT3; HMGA2; Liposarcoma; YEATS4

Indexed keywords

5' UNTRANSLATED REGION; ADULT; AGED; AMPLICON; ARTICLE; BINDING SITE; CARCINOGENESIS; CDK4 GENE; CENTROMERE; CHOP GENE; CHROMOSOME 12Q; DDIT3 GENE; DYRK2 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GADD153 GENE; GAS41 GENE; GENE; GENE AMPLIFICATION; GENE DISRUPTION; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; GENE PROBE; GENE REARRANGEMENT; GENE SEQUENCE; GENE TRANSLOCATION; HMGA2 GENE; HUMAN; HUMAN TISSUE; LIPOSARCOMA; MALE; MDM2 GENE; MYXOSARCOMA; ONCOGENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TSPAN31 GENE; TUMOR DIFFERENTIATION; YEATS4 GENE; CASE REPORT; CELL DIFFERENTIATION; CHROMOSOME 12; GENETICS; LIPOMA; METABOLISM; MIDDLE AGED; PATHOLOGY;

CDK4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; DDIT3 PROTEIN, HUMAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HIGH MOBILITY GROUP A2 PROTEIN; MDM2 PROTEIN, HUMAN; MESSENGER RNA; PROTEIN MDM2; TRANSCRIPTION FACTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG; YEATS4 PROTEIN, HUMAN;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CHROMOSOMES, HUMAN, PAIR 12; CYCLIN-DEPENDENT KINASE 4; FEMALE; GENE AMPLIFICATION; HMGA2 PROTEIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LIPOMA; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS;

EID: 42149187083     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23380     Document Type: Article

References (45)

1. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O, Turc-Carel C. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosomes Cancer 1999;24:30-41.
2. Fletcher C, Unni K, Mertens F, eds. World Health Organization classification of tumours pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002.
3. Binh MB, Sastre-Garau X, Guillou L, de Pinieux G, Terrier P, Lagacé R, Aurias A, Hostein I, Coindre JM. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol 2005;29:1340-7.
4. Fischer U, Heckel D, Michel A, JankaM, Hulsebos T, Meese E. Cloning of a novel transcription factor-like gene amplified in human glioma including astrocytoma grade I. Hum Mol Genet 1997;6:1817-22.
5. Munnia A, Schütz N, Romeike BF, Maldener E, Glass B, Maas R, Nastainczyk W, Feiden W, Fischer U, Meese E. Expression, cellular distribution and protein binding of the glioma amplified sequence (GAS41), a highly conserved putative transcription factor. Oncogene 2001;20:4853-63.
6. Llanos S, Efeyan A, Monsech J, Dominguez O, Serrano M. High-throughput loss-of-function screening identifies novel p53 regulators. Cell Cycle 2006;5:1880-5.
7. Park JH, Roeder RG. GAS41 is required for repression of the p53 tumor suppressor pathway during normal cellular proliferation. Mol Cell Biol 2006;26:4006-16.
8. Sirvent N, Forus A, Lescaut W, Burel F, Benzaken S, Chazal M, Bourgeon A, Vermeesch JR, Myklebost O, Turc-Carel C, Ayraud N, Coindre JM, et al. Characterization of centromere alterations in liposarcomas. Genes Chromosomes Cancer 2000;29:117-29.
9. Gabrielsson BG, Olofsson LE, Sjögren A, Jernås M, Elander A, Lönn M, Rudemo M, Carlsson LM. Evaluation of reference genes for studies of gene expression in human adipose tissue. Obes Res 2005;13:649-52.
10. Hostein I, Pelmus M, Aurias A, Pedeutour F, Mathoulin-Pélissier S, Coindre JM. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol 2004;202:95-102.
11. Heidenblad M, Hallor KH, Staaf J, Jönsson G, Borg A, Höglund M, Mertens F, Mandahl N. Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays. Oncogene 2006;25:7106-16.
12. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases. INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87.
13. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447-55.
14. Batchvarova N, Wang XZ, Ron D. Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153). EMBO J 1995;14:4654-61.
15. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992;6:439-53.
16. Vohl MC, Sladek R, Robitaille J, Gurd S, Marceau P, Richard D, Hudson TJ, Tchernof A. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res 2004;12:1217-22.
17. Akatsu Y, Saikawa Y, Kubota T, Akatsu T, Yoshida M, Kitagawa Y, Otani Y, Kumai K, Kitajima M. Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. Cancer Sci 2007;98:707-15.
18. Kim R, Ohi Y, Inoue H, Aogi K, Toge T. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis. Anticancer Res 1999;19:1779-83.
19. Los G, Benbatoul K, Gately DP, Barton R, Christen R, Robbins KT, Vicario D, Kirmani S, Orloff LA, Weisman R, Howell SB. Quantitation of the change in GADD153 messenger RNA level as a molecular marker of tumor response in head and neck cancer. Clin Cancer Res 1999;5:1610-18.
20. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005;41:2853-60.
21. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8.
22. Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene. HMGI-C, in benign mesenchymal tumours. Nat Genet 1995;10:436-44.
23. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, Fusco A. Role of the high mobility group A proteins in human lipomas. Carcinogenesis 2001;22:1583-91.
24. Quade BJ, Weremowicz S, Neskey DM, Vanni R, Ladd C, Dal Cin P, Morton CC. Fusion transcripts involving HMGA2 are not a common molecular mechanism in uterine leiomyomata with rearrangements in 12q15. Cancer Res 2003;63:1351-8.
25. Dal Cin P, Thomas A, Weremowicz S. An intragenic rearrangement of HMGA2 is not necessary for lipoma formation. Cancer Genet Cytogenet 2004;149:178-9.
26. Berner JM, Meza-Zepeda LA, Kools PF, Forus A, Schoenmakers EF, Van de Ven WJ, Fodstad O, Myklebost O. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas. Oncogene 1997;14:2935-41.
27. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O. Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions. Genes Chromosomes Cancer 2001;31:264-73.
28. Pentimalli F, Dentice M, Fedele M, Pierantoni GM, Cito L, Pallante P, Santoro M, Viglietto G, Dal Cin P, Fusco A. Suppression of HMGA2 protein synthesis could be a tool for the therapy of well differentiated liposarcomas overexpressing HMGA2. Cancer Res 2003;63:7423-7.
29. Goodwin G. The high mobility group protein. HMGI-C. Int J Biochem Cell Biol 1998;30:761-6.
30. Fedele M, Berlingieri MT, Scala S, Chiariotti L, Viglietto G, Rippel V, Bullerdiek J, Santoro M, Fusco A. Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 1998;17:413-18.
31. Zaidi MR, Okada Y, Chada KK. Misexpression of full-length HMGA2 induces benign mesenchymal tumors in mice. Cancer Res 2006;66:7453-9.
32. Schoenberg Fejzo M, Ashar HR, Krauter KS, Powell WL, Rein MS, Weremowicz S, Yoon SJ, Kucherlapati RS, Chada K, Morton CC. Translocation breakpoints upstream of the HMGIC gene in uterine leiomyomata suggest dysregulation of this gene by a mechanism different from that in lipomas. Genes Chromosomes Cancer 1996;17:1-6.
33. Gattas GJ, Quade BJ, Nowak RA, Morton CC. HMGIC expression in human adult and fetal tissues and in uterine leiomyomata. Genes Chromosomes Cancer 1999;25:316-22.
34. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007;315:1576-9.
35. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30.
36. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275:14394-400.
37. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, Parlow AF, Visone R, Pierantoni GM, Outwater E, Santoro M, Croce CM, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8.
38. Narita M, Narita M, Krizhanovsky V, Nuñez S, Chicas A, Hearn SA, Myers MP, Lowe SW. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 2006;126:503-14.
39. Miller CT, Aggarwal S, Lin TK, Dagenais SL, Contreras Jl, Orringer MB, Glover TW, Beer DG, Lin L. Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas. Cancer Res 2003;63:4136-43.
40. Maher EA, Brennan C, Wen PY, Durso L, Ligon KL, Richardson A, Khatry D, Feng B, Sinha R, Louis DN, Quackenbush J, Black PM, et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006;66:11502-13.
41. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007;25:725-38.
42. Shmueli A, Oren M. Mdm2: p53's lifesaver? Mol Cell 2007;25:794-6.
43. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer 2007;121:199-205.
44. Singer S, Socci ND, Ambrosini G, Sambol E, Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, Schwartz GK, Antonescu CR. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res 2007;67:6626-36.
45. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006;103:1888-93.